HU9602536D0 - Treatment of diabetic nephropathy with valsartan - Google Patents

Treatment of diabetic nephropathy with valsartan

Info

Publication number
HU9602536D0
HU9602536D0 HU9602536A HU9602536A HU9602536D0 HU 9602536 D0 HU9602536 D0 HU 9602536D0 HU 9602536 A HU9602536 A HU 9602536A HU 9602536 A HU9602536 A HU 9602536A HU 9602536 D0 HU9602536 D0 HU 9602536D0
Authority
HU
Hungary
Prior art keywords
valsartan
treatment
diabetic nephropathy
nephropathy
diabetic
Prior art date
Application number
HU9602536A
Other languages
Hungarian (hu)
Other versions
HUT76542A (en
Inventor
Gasparo Marc De
Nigel Levens
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU9602536(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of HU9602536D0 publication Critical patent/HU9602536D0/en
Publication of HUT76542A publication Critical patent/HUT76542A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
HU9602536A 1994-03-17 1995-03-07 Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy HUT76542A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH80094 1994-03-17

Publications (2)

Publication Number Publication Date
HU9602536D0 true HU9602536D0 (en) 1996-11-28
HUT76542A HUT76542A (en) 1997-09-29

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602536A HUT76542A (en) 1994-03-17 1995-03-07 Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy

Country Status (12)

Country Link
EP (1) EP0750500A1 (en)
JP (1) JPH09510225A (en)
CN (1) CN1143908A (en)
AU (1) AU1850695A (en)
BR (1) BR9507086A (en)
CA (1) CA2184712A1 (en)
CZ (1) CZ268896A3 (en)
FI (1) FI963611A0 (en)
HU (1) HUT76542A (en)
PL (1) PL316259A1 (en)
SK (1) SK117996A3 (en)
WO (1) WO1995024901A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0883401T3 (en) * 1996-02-29 2003-05-05 Novartis Ag AT1 receptor antagonist to stimulate apoptosis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
AU8996698A (en) * 1997-09-10 1999-03-29 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3043000A (en) * 1998-12-23 2000-07-31 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
AU2001285768B2 (en) 2000-06-22 2005-03-10 Novartis Ag Solid valsartan pharmaceutical compositions
AR032758A1 (en) 2000-07-19 2003-11-26 Novartis Ag SALES VALSARTAN, A PROCESS FOR ITS MANUFACTURING, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SALES FOR THE PREPARATION OF MEDICINES
AR033390A1 (en) * 2000-08-22 2003-12-17 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ATTA RECEIVER ANTAGONIST AND A POTENTIATOR OF THE INSULIN SECRETION, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PARTS KIT
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
CN1882334A (en) * 2003-11-14 2006-12-20 诺瓦提斯公司 AT1-receptor antagonists for treating nephrotic syndrome
TR200703568A1 (en) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formulations
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (en) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Non-steroidal antiinflammatory agents - for treatment of micro:vascular disease, e.g. diabetic retinopathy or diabetic nephropathy
ATE134624T1 (en) * 1990-02-19 1996-03-15 Ciba Geigy Ag ACYL COMPOUNDS
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
CZ268896A3 (en) 1997-03-12
FI963611A (en) 1996-09-13
HUT76542A (en) 1997-09-29
SK117996A3 (en) 1997-03-05
WO1995024901A1 (en) 1995-09-21
BR9507086A (en) 1997-09-16
CA2184712A1 (en) 1995-09-21
CN1143908A (en) 1997-02-26
JPH09510225A (en) 1997-10-14
EP0750500A1 (en) 1997-01-02
AU1850695A (en) 1995-10-03
MX9603999A (en) 1997-12-31
FI963611A0 (en) 1996-09-13
PL316259A1 (en) 1997-01-06

Similar Documents

Publication Publication Date Title
PL337362A1 (en) Treatment of diabetes by means of thiazolydinone and metformin
GB9411080D0 (en) Treatment
HU9602536D0 (en) Treatment of diabetic nephropathy with valsartan
EG21712A (en) Treatment of insulin resistance
EP0832204A4 (en) Treatment of insulin resistance
GB9405021D0 (en) Skin treatment composition
GB9606076D0 (en) Diabetes treatment
ZA973843B (en) Treatment of asthma with TNFR-lg.
GB9416410D0 (en) Effluent treatment
GB9415901D0 (en) Novel compounds and treatment
EP1126856A4 (en) Compounds and their therapeutic use with diabetic complications
GB9415900D0 (en) Novel compounds and treatment
GB9408084D0 (en) Medical treatment
GB9405046D0 (en) Skin treatment composition
NO963869D0 (en) Treatment of diabetic nephropathy with valsartan
GB9618290D0 (en) Treatment of diabetes
GB2285936B (en) Treatment of fluids
GB9410971D0 (en) Diabetes treatment
GB9609897D0 (en) Treatment of diabetes
GB2296238B (en) Improvements in or relating to effluent treatment
GB9412853D0 (en) Effluent treatment
GB9815149D0 (en) Treatment of diabetes
GB9812314D0 (en) Treatment of diabetes
GB2286824B (en) Wastewater treatment
GB9415920D0 (en) Novel compounds and treatment

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: NOVARTIS AG., CH

DFD9 Temporary prot. cancelled due to non-payment of fee